A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults
Status:
Recruiting
Trial end date:
2028-12-13
Target enrollment:
Participant gender:
Summary
This is a phase 2b, randomized, multicenter, parallel group, partially blind (to GSK3640254
doses [100, 150 and 200 milligrams {mg}]), active controlled clinical trial. It will aim to
investigate the safety, efficacy and dose-response of GSK3640254 compared to dolutegravir
(DTG), each given in combination with 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
(abacavir/lamivudine [ABC/3TC] or emtricitabine/tenofovir alafenamide [FTC/TAF])